Press release
ANGPTL3 Therapy Market Rises with Focus on Cardiovascular Health by 2025-2033 | Regeneron Pharmaceuticals, Inc., Arrowhead Pharmaceuticals Inc., Amgen Inc., Silence Therapeutics, Eli Lilly, Novartis AG
ANGPTL3 Therapy Market
The latest ANGPTL3-Lowering Therapy Market Report by DataM Intelligence offers a clear analysis of global trends, market size, key players, and growth drivers. Covering emerging technologies, evolving care models, and regulatory insights, it provides strategic intelligence to help stakeholders navigate the dynamic healthcare landscape through 2025-2033
Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access):
https://www.datamintelligence.com/download-sample/angptl3-lowering-therapy-market?ophp
ANGPTL3-lowering therapy targets angiopoietin-like 3 protein to reduce lipid levels and cardiovascular risk in patients with genetic dyslipidemia. The market is in early stages but gaining momentum with clinical trial success and growing interest in precision cardiometabolic therapies.
ANGPTL3-Lowering Therapy Market Competitors Overview:
Regeneron Pharmaceuticals, Inc., Arrowhead Pharmaceuticals Inc., Amgen Inc., Ionis Pharmaceuticals, Inc. (Akcea Therapeutics), Silence Therapeutics, Eli Lilly and Company, Novartis AG, Verve Therapeutics, Inc., and CRISPR Therapeutics, among others.
Important Industry Updates of 2024 and 2025:
✅ In May 2024, Arrowhead Pharmaceuticals recently presented new Phase 2 clinical data for Zodasiran (formerly known as ARO-ANG3), an investigational RNA interference (RNAi) therapy being developed for patients with mixed hyperlipidemia, a condition characterized by elevated levels of multiple types of blood lipids, such as cholesterol and triglycerides. Zodasiran works by targeting and reducing the production of angiopoietin-like protein 3 (ANGPTL3), a protein made in the liver that plays a key role in regulating lipid and lipoprotein metabolism.
ANGPTL3-Lowering Therapy Market Segments Overview:
∎ By Treatment Type (Monoclonal Antibodies, Antisense Oligonucleotides (ASOs), RNA Interference (RNAi) Therapies (siRNA), CRISPR-Based Gene Editing, Others)
∎ By Application (Familial Hypercholesterolemia (FH), Refractory Hyperlipidemia, Mixed Dyslipidemia, Cardiovascular Diseases, Others)
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/angptl3-lowering-therapy-market?ophp
Methodology and Scope:
This ANGPTL3-Lowering Therapy Market report is developed using a robust research methodology that combines primary interviews, insights from industry experts, and verified secondary sources such as company filings, trade journals, and trusted databases. It follows a bottom-up and top-down approach to ensure data accuracy through triangulation. The scope of the report covers current market trends, growth potential, and strategic developments across global and regional markets.
Regional Overview for ANGPTL3-Lowering Therapy Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Looking For Exclusive Full Report? Get it here: https://www.datamintelligence.com/buy-now-page?report=angptl3-lowering-therapy-market?ophp
The Report Includes:
➡ A descriptive analysis of demand-supply gap, market size estimation, SWOT analysis, PESTEL Analysis and forecast in the global market.
➡ Go-to-market Strategy.
➡ Neutral perspective on the market performance.
➡ Customized regional/country reports as per request and country level analysis.
➡ Potential & niche segments and regions exhibiting promising growth covered.
People Also Ask:
➤ What are the global sales, production, import, and export trends in the ANGPTL3-Lowering Therapy market?
➤ Who are the top manufacturers, and what are their output, pricing, and revenue figures?
➤ What key opportunities and challenges do vendors face in this market?
➤ Which product types, applications, or end-users are driving growth and holding market share?
➤ What are the main growth drivers and restraints affecting the ANGPTL3-Lowering Therapy market?
Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ANGPTL3 Therapy Market Rises with Focus on Cardiovascular Health by 2025-2033 | Regeneron Pharmaceuticals, Inc., Arrowhead Pharmaceuticals Inc., Amgen Inc., Silence Therapeutics, Eli Lilly, Novartis AG here
News-ID: 4103066 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
Japan Electronics Market to Reach US$ 162.66 Billion by 2032 | CAGR 4.3% | Kanto …
Japan Electronics Market Overview
The Japan electronics market reached US$ 111.16 billion in 2023, rising to US$ 116.15 billion in 2024, and is projected to reach US$ 162.66 billion by 2032, growing at a CAGR of 4.3% during the forecast period 2025-2032.
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/japan-electronics-market?Juli
Japan's electronics sector is among the most advanced and dynamic technology markets globally, recognized for precision…
Stationery Products Market to Reach US$ 193.7B by 2031 | CAGR 5.1% | Asia-Pacifi …
Market Overview
The Global Stationery Products Market was valued at US$ 130.1 billion in 2023 and is projected to reach US$ 193.7 billion by 2031, growing at a CAGR of 5.1% during the forecast period (2024-2031).
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/stationery-products-market?Juli
The market's growth is primarily driven by the rising global focus on education, increasing literacy rates, and expanding access to quality learning,…
Metal Recycling Market to Reach USD 92.2 Billion by 2031 | CAGR 6.8% | North Ame …
Market Size & Overview
The Global Metal Recycling Market reached US$ 54.5 billion in 2022 and is projected to reach US$ 92.2 billion by 2031, growing at a CAGR of 6.8% during the forecast period 2024-2031. The market growth is largely driven by rising environmental awareness and increasing sustainability initiatives, as industries aim to reduce dependence on primary metal extraction and mitigate volatility in global metal supply chains.
Get a Free Sample…
Prostate Cancer Drugs Market to Reach USD 28.10 Billion by 2033 | CAGR 8.1% | No …
Prostate Cancer Drugs Market Overview
The global prostate cancer drugs market was valued at US$ 13.22 billion in 2024 and is projected to reach US$ 28.10 billion by 2033, expanding at a CAGR of 8.1% during the forecast period 2025-2033. The market growth is primarily driven by the rising global incidence of prostate cancer, which is closely linked to the aging male population. Risk increases sharply after the age of 50…
More Releases for ANGPTL3
Familial Lipoprotein Lipase (LPL) Deficiency Market to Reach USD 2.41 Billion by …
Pune, India - December 2025 - The global Familial Lipoprotein Lipase (LPL) Deficiency Market, valued at USD 1.31 billion in 2024, is projected to reach USD 2.41 billion by 2034, growing at a 6.2% CAGR (2025-2034), according to Exactitude Consultancy. Increasing understanding of ultra-rare lipid disorders, advancements in gene therapy, and improved diagnostic capabilities are fueling strong market growth.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72017
Market Summary
The Familial…
Novel Hypercholesterolemia Drugs Market Surges as PCSK9 Inhibitors, siRNA Therap …
The Novel Hypercholesterolemia Drugs Market is undergoing a major transformation as next-generation lipid-lowering therapies gain global acceptance. With cardiovascular diseases remaining the leading cause of death worldwide, demand for therapies that achieve deeper, sustained LDL-cholesterol reduction has never been higher. The shift toward RNA-based therapies, long-acting injectables, gene-silencing mechanisms, and precision cardiology is accelerating market growth across North America, Europe, and Asia-Pacific.
Download Full PDF Sample Copy of Market Report @…
ANGPTL3 Inhibitor Market: Industry Set for Transformative Growth Fueled by Pipel …
DelveInsight's comprehensive report comes at a transformative juncture for the ANGPTL3 inhibitor segment, as the market pivots from single-product dominance to a vibrant, innovation-driven pipeline with the potential to overhaul treatment paradigms for cardiovascular and lipid disorders.
DelveInsight's comprehensive report, "Angiopoietin-like protein 3 (ANGPTL3) Inhibitor Market, Target Population, Competitive Landscape, and Market Forecast 2034 [https://www.delveinsight.com/report-store/angptl3-inhibitor-market-forecast?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" The report comes at a transformative juncture for the ANGPTL3 inhibitor segment, as the market pivots…
Global ANGPTL3-lowering Therapy Market (2025-2033): 30.9% CAGR Fueled by RNAi & …
The global ANGPTL3-lowering therapy market was valued at US$ 99.75 million in 2024 and is projected to reach US$ 1,096.42 million by 2033, growing at a compound annual growth rate (CAGR) of 30.9% during the forecast period 2025-2033.
Market Overview
ANGPTL3-lowering therapies target angiopoietin-like protein 3 (ANGPTL3), a liver-produced protein that regulates lipid metabolism. These therapies, including monoclonal antibodies, antisense oligonucleotides (ASOs), and RNA interference (RNAi) treatments, reduce low-density lipoprotein cholesterol (LDL-C)…
Homozygous Familial Hypercholesterolemia (HoFH) Market Massive Growth opportunit …
Introduction
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic lipid disorder characterized by extremely high low-density lipoprotein cholesterol (LDL-C) levels from birth, often exceeding 500 mg/dL. Caused by mutations in both alleles of the LDLR, APOB, or PCSK9 genes, HoFH leads to early-onset atherosclerosis, cardiovascular disease, and premature mortality if untreated.
Historically, management relied on lipid-lowering agents, LDL apheresis, and lifestyle modifications. However, the last decade has witnessed a paradigm shift with…
Homozygous Familial Hypercholesterolemia Market 2025 | Market Growth, Genetic Sc …
Homozygous Familial Hypercholesterolemia Market reached US$ 83.7 million in 2022 and is expected to reach US$ 101.8 million by 2030 growing with a CAGR of 2.5% during the forecast period 2023-2030, according to DataM Intelligence research report, as per DataM intelligence research report.
Homozygous Familial Hypercholesterolemia Market: Recent Industry Developments
United States
✅ Regeneron announced the FDA extension of Evkeeza use to children aged 5-11 with HoFH, making it the first ANGPTL3 inhibitor…
